In this episode, we explore nine groundbreaking stories in mental health and psychiatric medicine, covering everything from healthcare fraud to the latest advancements in drug trials. First, we dive into the recent charges brought by the US Department of Justice against executives at Done, a California-based telehealth company, for alleged healthcare fraud. Done is accused of prescribing over 40 million Adderall pills to patients without proper evaluation, raising concerns about the balance between increasing mental healthcare access and responsible prescribing practices.
Highlights from this month include Lumateperone, Lavender, treatment resistant smoking, and Clonidine patches and Tourettes. A new meta analysis published in Psychiatry Research sheds light on a critical question.
Learn how to address depression in older adults, identify the risk factors and triggers, distinguish depression from normal aging, and explore effective treatment options.
Psychiatric news covered in this episode: TMS for Teens, Olanzapine Serum Levels, Old Medication Pairing Emerges for Novel Alcoholism Treatment, Old Medication Pairing Emerges for Novel Alcoholism Treatment, Promising Option For Transitioning Insomnia Medications, Lithium's Anti-Suicide Effects in Question, Role of Omega-3 Supplements in Psychosis Risk Reduction, Caffeine and Anxiety: A Concerning Connection for Coffee Lovers.
Psychiatric news covered in this episode: FDA Grants Priority Review for MDMA Therapy, Benzodiazepine Withdrawal Perils, Lithium: Good for Bones?, Iloperidone Added to Anti-Psychotics with Mania Efficacy, Transdiagnostic Sleep and Circadian Treatment, A Door Closes for Clozapine-Resistant Schizophrenia, Therapy for Multi-Trauma PTSD.
Key strategies to empower you in reducing marijuana use among you. Join us as we delve into practical approaches to support teens in making healthier choices and navigating the stages of change.
You do not need to be an expert in borderline personality to help your patients. Dr. Mallo will introduce tactics that can be applied in different treatment settings.
Robert Meisner, MD, explores the latest developments in psychiatric treatment with ketamine and esketamine, including their differences and emerging insights for clinicians.
We no longer recommend medications as first-line treatment. Here are the current pharmacotherapy approaches for the treatment of insomnia. Here are the indications for the use of benzodiazepines, non-benzodiazepines, and sedating antidepressants, and we're going to understand the mechanism of action and how to use the newest medications, orexin antagonists.
Despite limitations in current depression and PTSD treatments, there is a renewed interest in the therapeutic potential of these medications, which we'll explore in this webinar.
RSS
-_-Benefits-Side-Effects-and-Review-of-Trials_Thumb.jpg?1727890706 "What You Need to Know About Gepirone (Exxua) _ Benefits, Side Effects, and Review of Trials_Thumb.jpg")
